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The syndrome of chronic fatigue, feverishness, diffuse pains, and other ~onstitutional 
complaints, often precipitated by an acute infectious illness and aggravated by physical 
and emotional stressors, has a lengthy history in the medical literature. The Centers for 
Disease Control (CDC) recently formulated a case definition, renaming the illness "chronic 
fatigue syndrome." Nevertheless, there remain few biological data that can validate the 
existence of this syndrome as distinct from a wide variety of other, largely psychiatric 
disorders, and little understanding of its pathogenesis. In the present study, basal plasma 
and cerebrospinal fluid levels of the monoamine metabolites, 3-methoxy-4-hydroxyphen- 
ylglycol (MHPG), 5-hydroxyindoleacetic acid (5-tlIAA), and homovanillic acid (HVA) 
were determined in 19 patients meeting CDC research case criteria for chronic fatigue 
syndrome and in 17 normal individuals. Patients with chronic fatigue syndrome showed 
a signij~cant reduction in basal plasma levels of MHPG and a significant increase in 
basal plasma levels of S-HIAA. Although the functional significance of these findings has 
not been definitively elucidated, they are compatible with the clinical presentation of a 
syndrome associated with chronic lethargy and fatigue, and with evidence of persistent 
immune stimulation, and lend support to the idea that chronic fatigue syndrome represents 
a clinical entity with potential biological specificity. 
Introduction 
The syndrome of chronic fatigue, feverishness, diffuse pains, and other constitutional 
complaints, often precipitated by an acute infectious illness and aggravated by physical 
and emotional stressors, has a lengthy history (Manningham 1750; Beard 1869). Alternate 
views have considered this disorder either to represent the physiological aftermath of an 
acute infectious event or other physical insult in emotionally susceptible individuals, or 
have emphasized the importance of the infectious onset, with constitutional symptoms 
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Table I. Centers for Disease Control (CDC) Case Criteria for Chronic Fatigue Syndrome 
Major criteria: (Patient must fulfill major criteria 1 and 2) 
1. New onset of persistent or relapsing, debilitating fatigue or easy fatigability that does not resolve with 
bedrest and is severe enough to impair average daily activity below 50% of premorbid activity level, 
lasting for a period of at least 6 months. 
2. Exclusion of other clinical conditions or medication effects by appropriate history, physical examination 
or laboratory tests. 
Minor criteria: (Patient must show 6 or more of the symptom criteria and 2 or more of the physical 
criteria, o r  8 or more of the symptom criteria) 
Symptom criteria (must have begun at or after onset of the fatigue and must be persistent or recurring) 
I. Mild fever or chills 
2. Sore throat 
3. Painful anterior or posterior cervical or axillary lymph nodes 
4. Generalized muscle weakness 
5. Myalgias 
o. Prolonged postexertional fatigue 
7. Headaches 
8. Migratory at~hralgia 
9. Neuropsychological complaints (including photophobia, transient scotomata, forgetfulness, 
irritability, confusion, depression, poor concentration) 
10. Sleep disturbance 





criteria (must be documented on at least two occasions, at least ! month apart) 
Low grade fever (oral T 37.6-38.6°C or rectal T 37.8-38.8"C) 
Nonexudative pharyngitis 
Palpable anterior or posterior cervical or axillaty lymph nodes 
(From Holmes et al 198~), 
emerging secondary to persistent immune stimulation and/or other lasting pathophysio- 
logic sequelae. Because no consistent infectious markers have been found in these patients, 
the hypothesis of a specific infectious etiology has not been universally accepted, nor has 
it been excluded. 
In order to facilitate identification of objective characteristics and improve compara- 
bility of research studies, the Centers for Disease Control (CDC) more recently formulated 
a working case definition, renaming the illness "chronic fatigue syndrome" (Holmes et 
ai 1988). Patients meeting criteria for the syndrome must have persistent or relapsing, 
debilitating fatigue for at least 6 months in the absence of any medical diagnosis that 
would explain the clinical presentation. Several symptom criteria are also required for 
diagnosis (Table 1). 
We recently proposed that the substantial clinical overlap between chronic fatigue 
syndrome and a variety of primary psychiatric illnesses reflects a disturbance in a final 
common biological pathway that may be precipitated by a variety of pathophysiological 
antecedents (infectious or noninfectious). We showed that patients with chronic fatigue 
syndrome demonstrate significant hypocortisolism that seemed likely to reflect a deficiency 
of the principal hypothalamic stimulus to the pituitary-adrenal axis, namely, corticotropin- 
releasing hormone (Demitrack et al 1991). These findings were of interest because hy- 
pocortisolism itself could contribute to many of the symptoms of chronic fatigue syndrome 
(e.g., lethargy, fatigue, sleep disturbance, myalgias, arthralgias, enhanced immune ac- 
tivity). Moreover, corticotropin-releasing hormone serves not only as the principal stim- 
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ulus to the pituitary-adrenal axis, but is itself a behaviorally active neurohormone whose 
central administration to animals and nonhuman primates induces signs of physiological 
and behavioral arousal, including activation of the sympathetic nervous system (Brown 
et al 1982), hyperresponsiveness to sensory stimuli (Swerdlow et al 1986), and increased 
locomotion (Sutton et al 1982). Hence, a deficiency of hypothalamic corticotropin-re- 
leasing hormone function or release could contribute to the profound lethargy and fatigue 
that are inherent characteristics of chronic fatigue syndrome, either through direct effects 
upon the central nervous system or indirectly by causing glucocorticoid deficiency. 
We report here a preliminary investigation of basal cerebrospinal fluid and plasma 
measures of the monoamine metabolites, 3-methoxy-4-hydroxyphenylglycol (MHPG), 
5-hydroxyindoleacetic acid (5-HIAA), and homovanillic acid (HVA) in patients with 
chronic fatigue syndrome and in normal individuals. Several observations originally 
prompted our interest in examining these neurochemicais. Fi~t, from a clinical perspec- 
tive, it has been suggested that chronic fatigue syndrome may be a form of major 
depression, an illness in which disturbances in these neurochemicals have been extensively 
studied. Second, activation of hypothalamic corticotropin-releasing hormone appears to 
be anatomically and functionally linked to another stress-responsive and arousal-producing 
neurotransmitter system, namely, the locus cemleus-noradrenergic system, lntracerebro- 
ventricular administration of corticotropin-releasing hormone increases the spontaneous 
discharge of locus ceruleus neurons (Valentino et al 1983 ). Nitroprusside and hemorrhage, 
two stimuli known to activate hypothalamic corticotropin-releasing hormone neurons, 
lead to similar degrees of activation of locus ceruleus neurons (Valentino 1988). Fur- 
thermore, the 13-adrenoceptor antagonist propranolol inhibits the enhanced conditioned 
fear response produced by the central administration of corticotropin-releasing hormone 
(Cole and Koob 1988). Hence, a putative deficiency of hypothalamic corticotropin- 
releasing hormone may be reflected as a decrease in noradrenergic function. Our interest 
in the metabolite 5-HIAA is due not only to the established role for its parent neuro- 
transmitter, serotonin, in the mediation of mood, sleep, pain perception, and appetite, 
but also because, in the periphery, serotonin itself acts as a vasoactive amine, released 
at sites of inflammation by a variety of stimuli. Multifocal pain and signs of inflammation 
are common, defining features of chronic fatigue syndrome. A final reason for studying 
monoamine neurotransmission stems from the emerging understanding of the bidirectional 
communication occurring between the nervous and the immune systems (Dunn 1988). 
Although a wide array of compounds participate in this communication process, certain 
observations suggest a significant role for the monoamines. For instance, perturbations 
of the immune system in the periphery may be associated with significant alterations in 
central monoaminergic activity (Bhattacharya et al 1988). Furthermore, peripheral im- 
munocytes possess receptors for a variety of monoamine neurotransmitters, and other 
lymphoid tissues are extensively innervated by automatic neurons (Livnat et al 
1985).Assessing the integrity of monoaminergic neurotransmission in the central nervous 
system and in the periphery may, therefore, help extend and clarify the results of our 
initial studies, and orient future work in this area. 
Subjects 
Only patients who had met the CDC research case definition for the chronic fatigue 
syndrome, and in whom no other medical diagnosis could be established, were included 
in the present study. Selection was also based on availability for the study duration, 
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ability to comply with the s~ct dietary and medication-free constraints of the study, and 
willingness to participate. Except for the severity criteria in the established case definition, 
illness severity per se was not considered in patient selection. Formally diagnosable current 
or past psychiatric illnesses are present in well over half of all reported case series of 
chronic fatigue syndrome. At the present time, however, a descriptive algorithm for the 
differentiation of primary psychiatric illnesses from chronic fatigue syndrome remains 
elusive in many, if not all, cases. Hence, it is difficult and often impossible to determine 
whether a psychiatric disorder is fully explanatory of the clinical presentation, a secondary 
manifestation of a primary disease process, or a coincident disease that modulates the 
presentation and course of the fatigue state. In our patient recruitment, rather than attempt 
to establish a definitive distinction between psychiatric illness and CFS per se, we chose 
as a systematic method~ ~,y an approach that characterizes psychopathology a priori, 
and therefore allows, a posteriori, an examination of the interaction of psychopathology 
with the definition of chronic fatigue syndrome. 
Using the above selection criteria, 19 patients were selected in a random fashion from 
among a larger cohort of 127 patients recruited between 1979 and 1988 at the National 
Institutes of Health (NIH) and participating in ongoing evaluations of chronic fatigue. 
The demographic and historical features of the study population were comparable with 
and representative of prior reported populations of chronic fatigue syndrome patients from 
this and other centers (Tobi et al 1982; Jones et al 1985; Straus et al 1985, 1988a). Of 
the 19 patients, 13 were women. The mean age for the entire group was 36.4 ± 1.9 
years, and the mean duration of illness was 7.4 ± l .!  years (range 1.8-19.9 years). At 
the time of entry into this study, 6 were employed full or part time and 13 were unem- 
ployed. All patients were fully ambulatory and not confined to bed. In 18 of the 19 
patients, the syndrome was precipitated by an acute febrile illness. In 7 subjects, the 
presence of acute infectious mononucleosis was documented I:y appropriate clinical and 
laboratory evaluation. In the remaining 11, the illness was documented by either clinical 
or laboratory report of the patient's referring physician, though a specific pathogen was 
not always indicated. All patients had undergone serial physical examinations and lab- 
oratory evaluations, described elsewhere (Demitrack et al 1991), for at least 2 years prior 
to study, during which time no alternative medical diagnoses could be established. Fifteen 
of the 19 patients had previously undergone epicutaneous skin testing with an aeroal- 
lergen/food battery screen (Straus et al 1988a) before entry into the present study. 
Seventeen normal volunteers (eight women, nine men) were recruited by newspaper 
advertisement from the Washington D.C. area. The mean group of the normal volunteers 
was 31.2 ± 2.2 years. Patient and normal volunteer study groups were matched for age 
within one decade (two-tailed, unpaired t-test, NS) and did not differ significantly in their 
gender distribution (Fisher's exact test, NS). All normal volunteers provided detailed 
medical histories and underwent physical and laboratory examinations, which revealed 
no evidence of current or past neurological, endocrtnological, cardiovascular, hepatic, 
renal, or hematological disease. An unstructured psychiatric interview revealed no evi- 
dence of current or past history of psychiatric illness or history of chronic fatigue in the 
volunteers themselves or in their first-degree relatives. 
All subjects abstained from the use of medications, alcohol, tobacco, and caffeine for 
at least 2 weeks prior to the study and were maintained on a modified low monoamine 
diet for at least 3 days prior to the study. Female subjects were studied during the follicular 
phase of the menstrual cycle (days I through 10). All testing was performed on an inpatient 
basis at the NIH Clinical Center. The study protocol was reviewed and approved by NIH 
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Institutional Review Boards. All subjects gave written informed consent prior to partic- 
ipation in the study. All of the patients and normal volunteers had previously been 
participants in our studies of hypothalamic-pituitary-adrenal function in patients with 
chronic fatigue syndrome (Demitrack et al 1991). 
Methods 
All subjects were ~dmitted to the NIH Clinical Center on the evening prior to the study, 
and were maintained on strict bedrest for at least 6 continuous hr prior to the study. Only 
water was consumed after midnight. An indwelling intravenous catheter was inserted into 
an antecubital vein at 8:00 AM. After 1 hr, and immediately prior to lumbar puncture, a 
venous blood sample was withdrawn in a prechilled glass tube containing potassium 
ethylenediaminetetraacetate (EDTA). The blood sample was centrifuged at + 40(2 within 
1 hr of collection and the plasma was decanted and frozen at -70°C until assayed. 
Lumbar punctures were performed in the lateral decubitus position between 9:00 AM and 
9:30 AM. Thirty milliliters of cerebrospinal fluid were withdrawn over 15-30 min. The 
first 12 ml were collected in a single pool in a chilled polyethylene tube. This pooled 
fraction was gently mixed, divided into 1 ml aliquots, immediately frozen on dry ice, 
and then stored at -70°(2 until assayed. 
The norepinephrine metabolite MHPO, the serotonin metabolite 5-HIAA, and the 
dopamine metabolite HVA were measured by means of high-pressure liquid chromatog- 
raphy with electrochemical detection, as previously described (Seppala et al 1984). ln- 
traassay and interassay variabilities ranged from 5.6% to 14.7% and from 4.6% to 5.8%, 
respectively. 
Prior to lumbar puncture, all patients were interviewed using the Diagnostic Interview 
Schedule, version III-A (DIS-III-A) (Robins and Helzer 1985). To assess the possible 
misdiagnosis caused by similarity in symptoms between the chronic fatigue syndrome 
and psychiatric disorders, v,~, employed a previously described method of scoring the 
DIS-III-A which was used in classifying psychiatric diagnoses in patients with chronic 
disease (Lustman et al 1986). Subsequently, the interviews were re-scored, including as 
behaviorally relevant the symptoms that were explicitly attributed to the fatigue syndrome. 
Interviews were scored by both methods to yield DSM-III-R diagnoses. When the age 
of onset of the chronic fatigue syndrome a~d age at which psychiatric problems occurred 
were within 1 year of each other, they were considered concurrent. 
All data are expressed as mean 4. 1 SEM. Between-group comparisons were performed 
using two-tailed, unpaired t-tests, employing a Bonferroni-adjusted a level to determine 
statistical significance. Data analyses were performed on a Macintosh SE/30 microcom- 
puter using the Statview 512 + statistical software package and on an Amdahl 470 V/8 
mainframe system using the BMDP statistical package. 
Results 
Basal Plasma and Cerebrospinal Fluid Measures of Monoamine Metabolites 
Basal plasma levels of MHPG were significantly reduced in patients with chronic fatigue 
syndrome compared with normals (8.3 _ 0.4 versus 10.8 ± 0.6 pmol/ml, df ffi 34, 
t = 3.384, p = 0.0018), whereas plasma levels of 5-HIAA were significantly elevated 
(67.3 4- 4.2 versus 37.3 - 5.9 pmol/ml, df ffi 34, t = -4.201, p ffi 0.002) (Table 
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Table 2. Plasma and Cerebrospinal Fluid Monoamine Metabolites in Patients with Chronic 
Fatigue Syndrome and in Healthy Controls 
n Mean SEM 
Cerebrospinal fluid 
MHPG Patients 19 41.5 1.3 
Normals 17 44.7 1.9 
5-HIAA Patients 19 I I 1.6 8.1 
Normals 17 95.1 10. I 
HVA Patients 19 ! 88.8 18.1 
Normals 17 191.6 27.7 
Plasma 
MHPG Patients 19 8.3" 0.4 
Normals 17 10.8 0.6 
5-HIAA Patients 19 67.3 b 4.2 
Normals 17 37.3 5.9 
HVA Patients 19 49.8 2.6 
Normals 17 55.7 5.6 
All sample values are expressed as pmol/ml. 
'p -- 0.0018; bp = 0.002; two-tailed, unpaired t-test; (Bonfen~oni-adjust~,d significance level = 0.0083). 
2). Interestingly, those patients (n -- 10) with previous evidence of a positive immediate 
hypersensitivity response to an epicutaneous aeroailergen/food battery screen tended to 
have higher levels of plasma 5-HIAA compared with those with no such response (72.0 
- 5.2 versus 53.6 _.+ 9.3 pmol/ml, p = 0.08, unpaired, two-tailed t-test). 
Plasma levels of HVA were no different in the patients with chronic fatigue syndrome 
compared with normals, nor were there any differences in cerebrospinal fluid monoamine 
metabolite levels between the patients and normais (Table 2). There were no significant 
gender-related differences in either the plasma or cerebrospinal fluid monoamine measures 
(data not shown). 
Relation between Psychiatric Diagnosis and Monoamine Measures 
As noted above, because the identification of psychiatric illnesses by standard diagnostic 
criteria includes many symptoms that are an inherent part of the definition of chronic 
fatigue syndrome itself (e.g., fatigue, lethargy, sleep disturbance), we first evaluated the 
structured interview results using restrictive criteria that excluded symptoms attributable 
to the chronic fatigue syndrome itself. By this method, 5 of 19 patients reported a lifetime 
history of major depression, 4 a lifetime history of anxiety disorder, and only 1 met 
criteria for somatization disorder. However, using criteria that included all symptoms as 
behaviorally relevant, 10 of 19 patients reported a lifetime history of major depressive 
illness, 4 reported a lifetime history of anxiety disorder, and 3 met criteria for somatization 
disorder. Given the occurrence of more than one diagnosis in 7 patients, a total of 13 of 
the 19 met criteria for a lifetime history of psychiatric illness. In 7 of the subjects, 
psychiatric illness appeared to precede the onset of the chronic fatigue syndrome. These 
findings are similar to those reported previously by members of our group and most others 
in studies of patients with chronic fatigue (Taerk et al 1987; Manu et al 1988, 1989; 
Kruesi et al 1989; Gold et al 1990; Hickie et al 1990). Although the comparison groups 
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were small, there were no evident trends nor statistically significant relationships bet-~veen 
a lifetime history of psychiatric illness (using either the restrictive or the inclusive criteria) 
or its onset relative to the onset of the chronic fatigue syndrome and any of the biological 
indices studied (two-tailed, unpaired t-test comparisons, data not shown). 
Discussion 
Patients with chronic fatigue syndrome demonstrated a significant reduction in mean basal 
plasma levels of the norepinephrine metabolite, MHPG, and a significant elevation in 
mean basal plasma levels of the serotonin metabolite, 5-HIAA, when compared with 
normal individuals. Corresponding levels of these metabolites in the cerebrospinal fluid 
of patients with chronic fatigue syndrome were normal. 
These results contr~st with the majority of studies of monoamine function in patients 
with melancholic depression, in whom elevated plasma norepinephrine and MHPG (Wyatt 
et ai 1971; Esler ~'t al 1982; Lake et al 1982; Jimerson et al 1983; Barnes et al 1983), 
increased levels of cerebrospinal fluid and urinary MHPG (Koslow et a11983), and reduced 
levels of cerebrospinal fluid 5-HIAA (van Praag et al 1970) have generally been detected. 
Furthermore, we observed no relationship between the presence or absence of a history 
of formally diagnosed psychiatric illness and the disturbances in monoamine metabolism 
in patients with chronic fatigue syndrome. Although the mean length of illness in the 
patients studied here was slightly longer than 7 years, there was no relation between 
overall duration of illness and any of the biological measures we report. These findings, 
however, may not generalize to patients with a shorter course of illness. A female 
preponderance of chronic fatigue syndrome has been reported in the literature. Despite 
the presence of a nonsignificantly larger percentage of female patients compared with 
female normals in our sample populations, we were unable to perceive a gender-related 
effect on the findings we report here. It should be cautioned, however, that the small 
sample sizes make a firm conclusion on the role of gender as a confounding variable 
tentative at this time. Though the causes and implications of these findings are not 
completely clear, a number of issues deserve comment and may help to sugb_st directions 
for future study. 
Norepinephrine is the principal neurotransmitter released from nerve endings of the 
sympathetic nervous system. Plasma levels of norepinephrine and its metabolites are 
determined by a variety of competing factors including the level of sympathetic nervous 
system activity and the rates of intraneuronal norepinephrine synthesis and release, the 
rates of intraneuronal reuptake and diffusion into extraneuronal tissues, and the site and 
methodology of sampling (Eisenhofer et al 1988). The principal metabolites of norepi- 
nephrine include the deaminated compounds, MHPO, and dihydmxyphenylglycol (DHPG). 
The basal and stimulated levels of plasma norepinephrine and DHPG are believed to 
reflect the intraneuronal disposition of norepinephrine and hence, may be the most sensitive 
indices of sympathetic nervous activity (Goldstein et al 1988). The functional significance 
of plasma MHPG is less clear, as a number of factors are known to influence its basal 
activity, including a phase shift in its circadian secretion, hemodynamic status, and the 
level of ongoing physical activity of the individual (Post et al 1984). In detecting reduced 
MHPG levels, we cannot rule out the presence of a circadian phase disturbance in the 
patients we studied. On the other hand, no subject was hemodynamically compromised, 
making this an unlikely source of interpretive error. All subjects, including the healthy 
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controls, were on strict bedrest for at least 6 continuous hr prior to lumbar puncture. 
However, because reduction in overall physical activity is a feature of chronic fatigue 
syndrome, this factor may contribute to the reduced basal plasma MHPG levels we found. 
Whether the reduction in basal plasma MHPG reflects an intrinsic diminution in sym- 
pathoneural activity in chronic fatigue syndrome cannot be definitively concluded from 
this study. However, the present observations take on particular interest when considered 
in the context of an illness in which there is also evidence of impaired activation of the 
hypothalamic-adrenal axis, presumably mediated by a reduction in the functional activity 
of hypothalamic corticotropin-releasing hormone (Demitrack et al 1991). As noted pre- 
viously, corticotropin-releasing hormone serves not only as the principal stimulus to the 
pituitary-adrenal axis, but is also a behaviorally active neurohormone whose central 
administration to animals and nonhuman primates induces signs of physiological and 
behavioral arousal, including activation of the sympathetic nervous system (Brown et al 
1982), These effects of corticotropin-releasing hormone are, in part, exerted through the 
established anatomical and functional connections with the principal arousal-producing 
neurotransmitter pathways involving the locus ceruleus-noradrenergic system (Valentine 
et al 1983; Valentine 1988; Cole and Koob 1988). Together with the results of the current 
report, these observations suggest that more detailed studies of basal and stimulated 
activity of the sympathetic nervous system in patients with chronic fatigue syndrome are 
warranted. 
5-HIAA represents the principal degradation product of serotonin metabolism. In 
humans, approximately 90% of serotonin is located in the mucosa of the gastrointestinal 
tract. Much of the remainder is stored in platelets or synthesized in neurons of the central 
nervous system, in the latter case where it functions as a neurotransmitter. Central nervous 
system ,~erotonin activity is thought to play an important role in several key physiological 
processes, including the regulation of sleep, mood, and the conscious perception of pain. 
However, a d~sturbance in central serotonin metabolism in patients with chronic fatigue 
syndrome seems unlikely from the present results, as cerebrospinal fl,id levels of 5- 
HIAA in the patients we describe here were no different from normal. 
How might the elevation in plasma levels of 5-HIAA be understood? One of the 
principal physiological roles for serotonin in the periphery is as a vasoactive amine, 
released at sites of inflammation by a variety of stimuli. Similar to histamine, serotonin 
can induce smooth muscle contractility and increase capillary permeability, and is thought 
to play an important role in the development of both immediate and delayed-type hy- 
persensitivity reactions. For instance, in mice, serotonin stimulates the late-acting T-cells 
which mediate the effects of delayed-type hypersensitivity (Ameisen et ai 1989). Fur- 
thermore, release and uptake of serotonin metabolites may be altered in a number of 
atopic and allergic conditions in humans (Ring and O'Connor 1979; Ring et al 1980; 
Malmgren et al 1982; Little et al 1983; Ring and Dorsch 1985). Patients with chronic 
fatigue syndrome are reported to have a higher incidence of allergic conditions (Straus 
et al 1988b). Indeed, it has been speculated that heightened allergic responsiveness may 
be a risk factor for the development of the syndrome. In particular, the diverse clinical 
and immunologic features have been argued to reflect an ongoing state of immune ac- 
tivation, with the persistent release of cytokines and inflammatory mediators in response 
to antigenic challenge (Cheney et al 1989; Chao et al 1990; Landay et al 1991). The 
observation, in the present study, of a trend toward higher levels of plasma 5-HIAA in 
those subjects with a history of immediate hypersensitivity to epicutaneous skin testing 
is in accord with these ideas. In addition to its pro-inflammatory effects, peripherally 
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secreted serotonin also potentiates the nociceptive effects of painful stimuli in both animals 
and humans (Nakano and Taira 1976; Giordano and Rogers 1989; Jensen et al 1990; 
Jensen et al 1991). Thus, an increase in peripheral levels of 5-HLAA in patients with 
chronic fatigue syndrome may reflect an increased turnover of serotonin, responsible in 
part for both the heightened allergic responsiveness in these patients as well as the 
symptomatic complaints of widespread musculoskeletal pain which characterize this syn- 
drome. 
A variety of immunologic abnormalities have been reported in patients with chronic 
fatigue syndrome. These abnormalities are diverse in character, relatively modest in 
magnitude, and of uncertain pathophysiological significance. Of particular note, none of 
these abnormalities have been shown to betu- any relationship to the clinical severity of 
the syndrome itself. Initial reports described abnormal patterns of antibody responses to 
a variety of infectious agents and nonspecific elevations in titers of antinuclear antibodies 
and immune complexes (Tobi et al 1982; Jones et al 1985; Straus et al 1985). Subsequent 
studies showed patterns of immunoglobulin subclass deficiencies, diminished natural killer 
cell number and function, alterations in T-cell subset number and tunction, and abnor- 
malities in serum cytokine levels or in vitro cytokine production (Kibner et al 1985; 
Caligiuri et al 1987; Komaroff et al 1988; Cheney 1989; Lloyd et al 1989; Straus et al 
1989; Chao et al 1990; Klimas et al 1990; Jones 1991). Landay et al (1991) and members 
of our group (Straus et al, unpublished observations) have recently described abnormalities 
in lymphocyte surface antigen cell adhesion marker expression suggesting a persistent 
immune stimulation in patients with chronic fatigue syndrome. The biological mechanisms 
that mediate these various immune disturbances are not clear. However, it is of interest 
to the present study that peripheral immunocytes and other lymphoid tissues possess 
receptors for a variety of monoamine neurotransmitters and receive an extensive inner- 
ration from the autonomic nervous system (Livnat et al 1985; Bonnet et al 1987; Fuchs 
et al 1988; van Tits et al 1990). Interactions between monoaminergic neurotransmitters 
and components of the immune system are therefore possible at both central and peripheral 
levels (Livnat et al 1985). This may occur through either central modulation of autonomic 
outflow to lymphoid tissues, or via changes in receptor responsiveness on the relevant 
target tissue. Whether the disturbances in monoamine function seen in the present study 
account for any of the immune abnormalities ,loted above, however, remains to be 
determined. 
It has been suggested that chronic fatigue syndrome is frequently precipitated by an 
acute infection. It is, therefore, relevant to speculate whether infections could alter neu- 
rotransmitter levels, and whether such alterations, in turn, could influence neuroendocrine 
or neuroimmune function. Southern and Oidstone (1986) have conducted a series of 
studies that bear on these speculations and which have led to the concept that chronic 
infection can disturb organismic homeostasis without damaging the morphologic ap- 
pearance or the essential biological machinery of cells. Using a poorly cytocidal murine 
RNA virus, lymphocytic choriomeningitis virus, they showed that persistent infection 
alters levels of acetylcholine synthesis in neuroblastoma cells in vitro (Oldstone et al 
197?}. In vivo, this virus displays a specific tropism for anterior pituitary somatotrophs, 
leading to a syndrome of retarded growth and abnormal glucose regulation in mice, due 
to a specific impairment in the secretion of growth hormone (Oldstone et al 1982). 
Moreover, persistent infection with this and several other agents, including the human 
immunodeficiency virus, is known to induce a variety of derangements of immune func- 
tton. It should be noted that in the present study, all but one patient reported an acute 
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infectious precipitant to their chronic fatigue. Hence, whether idiopathic chronic fatigue 
states presenting in the aftermath of an acute infection display psychobiological char- 
acteristics that differ from those fatigue states developing in the absence of an identifiable 
infectious stressor cannot be determined from the present data. 
For many years, it had been proposed that the protracted debility occurring in the 
aftermath of an acute infection reflects the presence of preexisting psychological morbidity 
(Imboden et al 1959). Indeed, this argument can be made for chronic fatigue syndrome 
as well. Most studies discerned that the prevalence of formally diagnosed psychiatric 
illness was higher in patients with either chronic fatigue or chronic fatigue syndrome than 
in the general population, and often preceded the onset of the fatigue syndrome (Taerk 
et al 1987; Manu et al 1988, 1989; Kruesi et al 1989; Gold et al 1990). In only one study 
was the prevalence of psychiatric illness reported to be comparable to that of the general 
population, and to follow, rather than precede the development of the chronic fatigue 
(Hickie et al 1990). However, in the absence of reliable biological measures to identify 
this syndrome, and given that most established psychiatric diagnostic systems include 
fatigue as a symptom of psychiatric disorder, the use of phenomenological criteria alone 
has introduced an unavoidable circularity of reasoning in establishing a definitive dis- 
tinction between chronic fatigue that is separate from, as opposed to a feature of, a 
psychiatric illness. Though results of the present investigation do not validate the construct 
of chronic fatigue syndrome as a discrete medical condition, they suggest specific bio- 
logical differences between patients with this illness and the majority of patients with the 
melancholic form of major depression. 
We conclude that, given the growing body of data that implicate alterations in central 
and peripheral neurotransmitter function in the pathophysiology of behavioral disorders, 
the strict etiologic distinction between either "psychological" or "physical" causes in our 
understanding of this puzzling syndrome no longer seems entirely useful. 
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